icon-folder.gif   Conference Reports for NATAP  
 
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
 
 
 
Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-na´ve Patients and Prior Null Responders
 
 
  Reported by Jules Levin
Presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases,
November 1-5, 2013, Washington, D.C.
 
Eric Lawitz1, Christophe Hezode2, Peter Varunok3, Paul J Thuluvath4, Tolga Baykal5, Mudra Kapoor5,
Sandra Sinisi Lovell5, Tianli Wang5, Tami Pilot-Mathias5, Regis A Vilchez5, Barry Bernstein5
1The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, United States; 2Assistance Publique Hopitaux de Paris, Paris, France;
3Premier Medical Group of the Hudson Valley, PC, Poughkeepsie, New York, United States; 4The Institute for Digestive Health and Liver Disease at Mercy, Baltimore, Maryland, United States; 5AbbVie Inc., North Chicago, Illinois, United States

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif